The Claim
In healthy adults aged 50–85, intermittent low-dose rapamycin (5 mg or 10 mg weekly) administered over 48 weeks does not significantly reduce visceral adiposity compared to placebo, with no difference observed between dose levels (p = 0.942), suggesting limited impact on this metabolic health parameter in normative aging populations.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking low doses of a drug called rapamycin once a week doesn’t seem to reduce belly fat in healthy older adults after nearly a year, whether they take 5 mg or 10 mg — it’s about the same as taking a dummy pill.
See the scientific wording
Intermittent low-dose rapamycin does not significantly reduce visceral adiposity in healthy adults aged 50–85 after 48 weeks, with no change observed across 5 mg or 10 mg weekly doses compared to placebo (p = 0.942), indicating limited impact on this metabolic health metric in normative aging populations.
What the research says
1 studyStudy: Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results
The study tested weekly low-dose rapamycin in older adults and found it didn’t reduce belly fat after a year, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.